Home

Pharmacology

Read time: 2 min

Congress highlights

Inflammation and glutamate dysregulation: unravelling the aetiology of schizophrenia

Reduced glutamatergic signalling and immune dysregulation are two major aetiological hypotheses in...

Read time: 2 min

Congress highlights

Highlights from ECNP 2021 — Day 4 — October 5th

Welcome to Progress in Mind’s live coverage of ECNP 2021. This 34th Congress of the European...

Read time: 3 min

Congress highlights

Highlights from ECNP 2021 — Day 3 — October 4th

Welcome to Progress in Mind’s live coverage of ECNP 2021. This 34th Congress of the European...

Read time: 3 min

Congress highlights

Highlights from ECNP 2021 — Day 2 — October 3rd

Welcome to Progress in Mind’s live coverage of ECNP 2021. This 34th Congress of the European...

Read time: 3 min

Congress highlights

Highlights from ECNP 2021 — Day 1 — October 2nd

Welcome to Progress in Mind’s live coverage of ECNP 2021. This 34th Congress of the European...

Read time: 3 min

Satellite symposium

Promising data in depression associated with emotional blunting or trauma

Treatment for depression should be tailored to individuals’ history and presentation....

Read time: 2 min

Congress highlights

Preclinical pearls offer insights into migraine sex differences and sensory thresholds

Speaking at #MTIS2020, Professor Frank Porreca, University of Arizona, USA, identified recent...

Depression, Schizophrenia

Read time: 3 min

Congress highlights

Why do we need new treatments for major depressive disorder and schizophrenia?

Atypical antipsychotics are the mainstay of treatment for schizophrenia and a therapeutic option as...

Depression, Schizophrenia

Read time: 4 min

Congress highlights

Lifestyle, the gut, and mental health

Interventions to lower the risk for cardiovascular disease and metabolic syndrome, correction of...

Read time: 3 min

Congress highlights

Real world study casts new light on potential of polypharmacy

The fact that 20-25% of patients with schizophrenia are treated with more than one antipsychotic1...

Read time: 4 min

Congress highlights

CGRP – new perspectives in headache management

Three new takes on the potential for calcitonin gene-related proteins were presented at this year...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind MENA Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind Greece Continue to Progress in Mind South East Asia Continue to Progress in Mind Middle East & Africa Continue to Progress in Mind United Kingdom Continue to Progress in Mind Sweden Continue to Progress in Mind Norge Continue to Progress in Mind Denmark Continue to Progress in Mind Finland Continue to Progress in Mind Japan RC Continue to Progress in Mind България Continue to Progress in Mind Israel Continue to Progress in Mind Sweden Continue to Progress in Mind Finland Continue to Progress in Mind Ukraine Continue to Progress in Mind Belgium & Luxembourg Continue to Progress in Mind Switzerland Continue to Progress in Mind Germany Continue to Progress in Mind Austria

You are leaving Progress in Mind

Continue to

Cancel

You are leaving

Progress in Mind Middle East and Africa
HCP Access verification required

To gain access, please provide details to verify you are a healthcare professional.

If you are not located in Middle East and Africa click here.

Already registered Register

Login as a registered health care professional

Please enter your email to continue

Register as a health care professional

Please enter your email to continue

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

Accept

Decline